APA

Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M. A. M., Kruimel J. W., Lenaerts K., Hanssen N. M. J., Conchillo J. M., Jonkers D. M. A. E. & Masclee A. A. M. (20141020). Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. : Alimentary pharmacology & therapeutics.

Chicago

Mujagic Z, Ludidi S, Keszthelyi D, Hesselink M A M, Kruimel J W, Lenaerts K, Hanssen N M J, Conchillo J M, Jonkers D M A E and Masclee A A M. 20141020. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. : Alimentary pharmacology & therapeutics.

Harvard

Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M. A. M., Kruimel J. W., Lenaerts K., Hanssen N. M. J., Conchillo J. M., Jonkers D. M. A. E. and Masclee A. A. M. (20141020). Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. : Alimentary pharmacology & therapeutics.

MLA

Mujagic Z, Ludidi S, Keszthelyi D, Hesselink M A M, Kruimel J W, Lenaerts K, Hanssen N M J, Conchillo J M, Jonkers D M A E and Masclee A A M. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. : Alimentary pharmacology & therapeutics. 20141020.